News Article | May 1, 2017
T cells are the "brain" of our immune system, so understanding how they sense and respond to antigen is extremely important. Until now we did not know how antigen binding to the T cell receptor triggers an intracellular activation response, or why the receptor does not signal when it is not bound to antigens. Electrostatic interactions between proteins (the receptor) and the membrane play a key role here. Now, there is a tool for measuring electrostatic membrane interactions in cells. Yuanqing (Alex) Ma, a PhD student of UNSW Scientia Professor and Imaging Centre of Excellence Deputy Director Katharina Gaus, was the lead author on a paper in Nature Biotechnology. Alex and the team designed and built a Förster resonance energy transfer (FRET) sensor. Alex said the membrane charge sensor measures the electric potential at the inner leaflet of cell plasma membrane – a different membrane property from the transmembrane potential often known in the field of neuroscience. "We've made a very cool tool using some nifty science that allows us to measure and see how T cells work," he said. "Our FRET sensor can measure tiny charges in living cells. And this lets us know how the membrane environment affects the T cell receptor and why it signals or not. The idea of the sensor design was actually quite simple, but getting the idea into action was not straight forward, Alex said. "There was a lot of trial and error in building the sensor and then even more when we began to test the sensor," he said. "Once we had tested the sensor outside of the cell, we had to test it inside the cell – which was also quite tricky. There are so many unpredictable factors that occur within a cell that often complicate our interpretation of the results. As a result, multiple controls were made to justify the result, which was tough." Another tool the team developed recently is a sensor that changes colour when the T cell receptor becomes clustered, reported in the journal Nature Communications. This sensor too works in living cells. Now UNSW researchers can monitor the membrane environment with the charge sensor, and the dynamics of the receptor with the clustering sensor. "These sensors provide us with the ability to map membrane charges and receptor dynamics in a cell over time, which has increased our ability to understand the biological function of membrane charge in different cell activities," Alex said. "This was difficult before due to lack of tools." One of the things the sensors have helped the researchers understand is how the membrane lipid environment affects the structure of the T cell receptor during an immunological response. Professor Gaus said they can now follow how T cell activation is regulated. "Before this work we could only guess why the receptor does not signal in resting cells," she said. "These sensors were a tour de force by Alex – it was not easy, for example, to tune the sensor to the range in which membrane charges switch the receptor on and off. "We have the very first direct evidence that electrostatic interactions regulate T cell receptor signalling." The team will use the tools made in the lab at UNSW to better understand how T cell signalling begins and is regulated. "We look forward to putting them to work and discovering just how our immune system triggers downstream responses," Professor Gaus said. Explore further: New model of T cell activation More information: Yuanqing Ma et al. A FRET sensor enables quantitative measurements of membrane charges in live cells, Nature Biotechnology (2017). DOI: 10.1038/nbt.3828 Yuanqing Ma et al. An intermolecular FRET sensor detects the dynamics of T cell receptor clustering, Nature Communications (2017). DOI: 10.1038/ncomms15100
News Article | February 15, 2017
WINNIPEG, Manitoba, Feb. 15, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce that Harry Glorikian has joined its Business Advisory Board. Mr. Glorikian has over 30 years of private and public company success in the biomedical and life sciences industries. He is recognized as a global innovator with high-profile consulting, executive and board experience and a passion for data driven medical diagnostics. Mr. Glorikian’s notable recent experience includes roles as Entrepreneur in Residence to GE Ventures – New Business Creation Group and as a member of the board of directors of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company) and Evidation Health (a digital health startup launched with support from GE Ventures). He is also a co-founder and an advisory board member of DrawBridge Health (a diagnostics startup launched with support from GE Ventures). Previously Mr. Glorikian co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories. “With the addition of Harry Glorikian to the Business Advisory Board, 3DS has gained tremendous insight into the development and commercialization of cutting-edge medical diagnostics,” noted Jason Flowerday, CEO of 3DS. “Mr. Glorikian has a track record of innovation and commercial success. His addition to the team is a very positive step forward for 3DS.” Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. He has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets. Mr. Glorikian is also author of the recently published and highly-relevant book, “Commercializing Novel IVDs: A Comprehensive Manual for Success.” An IVD is an in-vitro diagnostic device which is the type of diagnostic tool that 3DS is currently developing. Mr. Glorikian’s unique manual provides an overview of the major components to IVD development, from product conception through commercialization. His understanding of the diagnostic commercialization process in the context of clinical utility and cost effectiveness is an enormous asset to 3DS. 3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 20 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com. This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
News Article | February 21, 2017
QUINCY, Mass.--(BUSINESS WIRE)--Shields Health Solutions, a creator of specialty pharmacies for hospitals and health systems nationwide, today announced Prashant K Dilwali has joined the company’s executive team as Director of Business Operations. In his new role Prashant is responsible for establishing best practices across the patient support systems that the company has put in place to serve thousands of chronically ill patients. He also provides support identifying and analyzing new business opportunities. “Prashant is widely recognized as one of the most brilliant minds in healthcare today and we are delighted to have him join our growing executive team,” said Jack Shields, CEO, Shields Health Solutions. “We are adding the top talent in the country to our executive team right here in Quincy, heading into another year of double-digit growth. I know Prashant will play a vital role helping us meet the aggressive goals we have set out for the next few years, especially because we put patient health above all else and he is responsible for ensuring our operations continue to be the best in the industry at doing just that.” Prior to joining Shields, Prashant was Director of Finance at US Anesthesia Partners where he was responsible for budgeting and analytics. He has worked as a turnaround management consultant at Alvarez & Marsal’s Healthcare Industry Group – implementing both financial and operational restructuring. Prashant has also worked at Trinity Partners and Scientia Advisors as a strategy consultant to healthcare and life sciences companies – identifying new business opportunities and forecasting market capture. Prashant holds a Masters of Health Administration from the Johns Hopkins Bloomberg School of Public Health and a Bachelors of Science in Biology with a minor in Economics from the Massachusetts Institute of Technology. About Shields Health Solutions Shields Health Solutions partners with hospital leaders on every aspect of specialty pharmacy creation and management. The company provides the fastest, lowest risk model for Hospitals to create a hospital-owned specialty pharmacy business, eliminating risks associated with Limited Distribution Drug (LDD) contracts, payor contracts, pharmacy accreditations, infrastructure set up and more. Shields Health Solutions handles it all, whether hospital leaders want to build from scratch or add specialty capabilities to their existing pharmacy programs. In 2012 Shields Health Solutions broke new ground by introducing the first hospital-owned specialty pharmacy for a health system. Today many of the most respected hospitals in the country, including UMass Memorial, Fairview Health Services and Hartford Healthcare, are serving their chronically ill, complex patient populations using specialty pharmacy best practices developed collaboratively with Shields. The breakthrough of Shields Specialty Pharmacy is based on 40 years of partnerships with 30 hospital systems, building Shields Dialysis Centers, Shields Advanced Imaging Centers (Shields MRI) and Shields Radiation Therapy Centers. What we are doing today with Specialty Pharmacy is once again bringing best practices into a new area of healthcare, returning patients to the center of the care model, while helping healthcare leaders deliver better care more efficiently. Today, Shields Health Solutions is one of the fastest growing companies in America.
Korea Institute of Science, Technology and Scientia | Date: 2014-04-02
A composition for preventing and/or treating dementia and ameliorating memory impairment and/or improving memory, comprising one or more arylnaphthalene lignan derivatives, such as Justicidin A, 5-methoxyjusticidin A, Chinensinaphthol, and a pharmaceutically-acceptable salt thereof, as active ingredient.
Korea Institute of Science, Technology and Scientia | Date: 2014-04-02
The present invention relates to a pharmaceutical composition for preventing and/or treating dementia comprising extracts of Monsonia sp.; a food composition for preventing and/or improving dementia comprising extracts of Monsonia sp.; and a method of preparing an extract of Monsonia sp. with excellent inhibitory effect on the formation of -amyloid. The plant extract can inhibit the formation of -amyloid which has been known as a factor causing the dementia, especially Alzheimers disease, thereby being used for preventing, improving and/or treating the dementia.
Scientia | Date: 2013-11-29
Provided are methods for disrupting dipolar interactions in vivo and in vitro, as wells as treating conditions associated with abnormal cell growth, by subjecting to an artificial, stable magnetic field. Also provided are assays involving an artificial, stable magnetic field. Additionally, the exposure of an artificial, stable magnetic field may be combined with other non-magnetic therapy in treatment or assays.
Scientia | Date: 2010-04-02
A guidewire device comprising: a micro-fabricated elongated outer member having an outer surface and an interior surface forming a lumen extending from a proximal end to a distal end; an outer elastomer laminate layer in contact with at least a portion of said outer surface; and an inner member disposed within a substantial portion of said lumen, and embodiments thereof.
Scientia | Date: 2010-04-02
A guidewire device comprising an elongated outer member having an outer surface and an interior surface forming a lumen extending from a proximal end to a distal end, wherein an outer diameter of said distal end is larger than an outer diameter of said proximal end; and an inner member disposed within a portion of said lumen, and embodiments thereof.
Scientia | Date: 2014-12-04
The disclosure provides oral solid particle formulations comprising of an iodinated imaging agent and at least one taste masking agent showing improved bioadhesive properties, and are also useful for imaging of the gastrointestinal tract.
Scientia | Date: 2016-05-18
Micro-cutting machines for forming cuts in catheters, guidewires, and similar products, are disclosed, including a micro-cutting machine that can directly control the dimensions of the resultant beams (308, 314, 510, 520) being cut into products, and that can capture images of each cut for feedback control and accuracy verification.